Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation

Journal of Gene Medicine

Volumn 5, Issue 10, 2003, Pages 860-867

  Zhang, Zhujun ^a   Shirakawa, Toshiro ^b   Hinata, Nobuyuki ^b   Matsumoto, Akira ^a   Fujisawa, Masato ^b   Okada, Hiroshi ^b   Kamidono, Sadao ^b   Matsuo, Masafumi ^a   Gotoh, Akinobu ^a,b  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Gene therapy; Radiation

Indexed keywords

ADENOVIRUS VECTOR; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; CYTOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; MESSENGER RNA; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL KILLING; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE THERAPY; WILD TYPE; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BLADDER TUMOR; CELL CULTURE; DOSE RESPONSE; GENE THERAPY; GENE VECTOR; GENETICS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; RADIATION RESPONSE;

ADENOVIRIDAE; ANIMALS; COMBINED MODALITY THERAPY; CYTOSINE DEAMINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 1842818714     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.408     Document Type: Article

References (33)

1. Lerner SP, Skinner DG. Radical cystectomy for bladder cancer. In Comprehensive Textbook of Genitourinary Oncology. Vogelzang NJ, Shipley WU, Scardino PT, Coffey DS (eds). Williams & Wilkins: Philadelphia, 1996; 442-463.
2. Fossa SD, Ous S, Espetveit S, et al. Patterns of primary care and survival in 336 consecutive unselected Norwegian patients with bladder cancer. Scand J Urol Nephrol 1992; 26: 131-138.
3. Fossa SD, Waehre H, Aass N, et al. Bladder cancer definitive radiation therapy of muscle-invasice bladder cancer. A retrospective analysis of 317 patients. Cancer 1993; 72: 3036-3043.
4. Scher HI, Shipley WU, Herr HW. Cancer of the bladder. In Cancer Principles and Practice of Oncology (5th edn), vol. 1. Devita VT Jr, Hellman S, Rosenberg SA (eds). Lippincott-Raven: Philadelphia, 1997; 1300-1322.
5. Venturini M, Merlano M, Michelotti A, et al. Neo-adjuvant or definitive alternating chemotherapy and radiotherapy for infiltrating bladder cancer. Am J Clin Oncol 1989; 12: 63-67.
6. Rieger KM, Little AF, Swart JM, et al. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer 1995; 72: 683-690.
7. Cooper MJ, Haluschak JJ, Johnson D, et al. p53 mutations in bladder carcinoma cell lines. Oncol Res 1994; 6: 569-579.
8. Bubenik J, Baresova M, Viklicky V, et al. Established cell line of urinary bladder carcinoma (T24) containing tumor-specific antigen. Int J Cancer 1973; 11: 765-773.
9. Kimiya K, Naito S, Soejima T, et al. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, kk47/ADM. J Urol 1992; 148: 441-445.
10. Shirakawa T, Sasaki R, Gardner TA, et al. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells. Int J Cancer 2001; 94: 282.
11. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3: 207.
12. Yajima T, Yagihashi A, Kameshima H, et al. Quantitative reverse transcription-PCR assay of the RNA component of human telomerase using the Taqman fluorogenic detection system. Clin Chem 1998; 44: 2441-2445.
13. Gleave M, Hsieh JT, Gao CA, et al. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51: 3753.
14. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
15. Tomoko RP, Xu R, Philipson L, et al. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997; 94: 3352-3356.
16. Zweibel JA, Nagler C, Smiley JK, et al. Clinical trials of adenovirus-p53 gene therapy. Oncology 1998; 12: 1173-1175.
17. Pagliaro LC. Gene therapy for bladder cancer. World J Urol 2000; 18: 148-151.
18. Wood M, Perrotte P, Onishi E, et al. Biodistribution of an adenoviral vector carrying the luciferase reporter gene following intravesical or intravenous administration to a mouse. Cancer Gene Ther 1999; 6: 367-372.
19. 5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma. Clin Cancer Res 2000; 6: 185-192.
20. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999; 59: 325-330.
21. Li D, Duan L, Freimuth P, et al. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181.
22. Stevenson SC, Rollence M, White B, et al. Human adenovirus serotypes 3 and 5 bind to two different cellular receptors via the fiber head domain. J Virol 1995; 69: 2850-2857.
23. Freimuth P. A human cell line selected for resistance to adenovirus infection has reduced levels of the virus receptor. J Virol 1996; 70: 4081-4085.
24. Huber BE, Richards CA, Krenitsky TA, et al. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy. Proc Natl Acad Sci U S A 1991; 88: 8039-8043.
25. Khil M, Kim J, Mullen C, et al. Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine-deaminase gene. Clin Cancer Res 1996; 2 53-57.
26. Hanna NN, Mauceri HJ, Wayne JD, et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997; 57: 4205-4209.
27. Pederson LC, Buchsbaum DJ, Vickers SM, et al. Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma. cells in vitro and in vivo. Cancer Res 1997; 57: 4325-4332.
28. Rogulski KR, Kim JH, Kim SH, et al. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther 1997; 8: 73-85.
29. Yoshikawa R, Kusunoki M, Yanagi H, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001; 61: 1029-1037.
30. Sasaki R, Shirakawa T, Zhang Z, et al. Additional gene therapy with AD5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001; 51: 1336-1345.
31. Stevens CW, Zeng M, Cerniglia GJ, et al. Ionizing radiation greatly improves gene transfer efficiency in mammalian cells. Hum Gene Ther 1996; 7: 1727-1734.
32. Zeng M, Cerniglia GJ, Eck S, et al. High-efficiency stable gene transfer of adenovirus into mammalian cells using ionizing radiation. Hum Gene Ther 1997; 8: 1025-1032.
33. Shirakawa T, Gardner TA, Ko SC, et al. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol 1999; 162: 949-954.